Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ramses comparative claims "unsubstantiated" -- proposed FTC consent agreement.

This article was originally published in The Tan Sheet

Executive Summary

RAMSES COMPARATIVE CLAIMS BARRED BY PROPOSED FTC CONSENT AGREEMENT unless Norcross, Ga.-based London International "possesses and relies upon competent and reliable scientific evidence to back up the claims" for the latex condoms, the Federal Trade Commission reported Sept. 3. The consent agreement was spurred by advertising claims that Ramses is "30% stronger than the leading brand," which FTC called "unsubstantiated and deceptive."

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS087512

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel